DTIL · Precision BioSciences, Inc.

The thesis

Precision BioSciences' hepatitis B gene-editing case still rests on one quantified liver-biopsy result in one patient, and the company's guided year-end 2026 update decides whether it replicates. The adjusted daily close was $6.78 on 22 October 2026, above the $6.22 close of 25 September 2026 that marks the recovery boundary.

The narrative is maturing: the May biopsy story is well known, and the most recent company news is the 24 August 2026 Duchenne dosing announcement. A search of company releases and SEC filings on 23 October 2026 found no clinical release since the 6 August 2026 second-quarter report. The shares are 26.9% below their 52-week high of $9.28 and changed -6.5% over three months. Biopsies without a comparable drop in viral DNA would break the clinical premise.

Bullish and bearish views on Precision BioSciences, Inc.

The bull case on Precision BioSciences, Inc. (DTIL), in brief: Liver tissue showed the intended effect. The bear case: Replication is still missing.

Bull case

• Liver tissue showed the intended effect. On 27 May 2026, Precision reported a 1-log reduction in cccDNA-derived transcripts (covalently closed circular DNA, the hepatitis B virus's persistent reservoir) after two 0.4 mg/kg doses in one patient's biopsy. The company's release said less than 1% of cccDNA remained.
• Blood markers add a second measurement. At the 4 May 2026 data cutoff, Precision reported sustained loss of detectable pregenomic RNA in all evaluable patients who had detectable levels before treatment. The 6 August 2026 results release said the loss had continued for up to six months.
• A second program is now dosing. Precision announced the first patient dosed in the Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD, a Duchenne muscular dystrophy candidate, on 24 August 2026. The company guided further clinical updates for PBGENE-HBV and PBGENE-DMD to year-end 2026.
• Shares have held above the September low. The adjusted daily close was $6.78 on 22 October 2026, versus $6.22 on 25 September 2026. The 14-day relative strength index was 58.2, a mid-range reading.

Bear case

• Replication is still missing. The 6 August 2026 results release quantified the 1-log biopsy result in one patient and described a second patient's biopsy only qualitatively. Additional biopsies without a comparable reduction would leave the finding as a single observation.
• Infusion safety needs more doses. The 27 May 2026 clinical release reported severe hypotension and serious adverse events at the 0.8 mg/kg dose, after which the company used longer infusions and steroids. It also reported no dose-limiting toxicities across 16 patients.
• Runway depends on financing access. Precision reported $112.4 million of cash, cash equivalents and restricted cash at 30 June 2026. The 6 August 2026 guidance of funding through 2028 includes availability of an at-the-market equity facility, so new shares can arrive before new data.
• No new clinical disclosure has followed. The newest company item is the 24 August 2026 dosing announcement. Price movement since then has come without fresh results.

Price setup

The adjusted daily close was $6.78 on 22 October 2026. That is 26.9% below the 52-week high of $9.28 and above the $6.22 close of 25 September 2026.

The three-month change is -6.5%, a much smaller decline than the -21.7% reported in the 10 October 2026 note, which measured a different window. The 14-day relative strength index of 58.2 shows no stretched buying.

Crowding evidence is limited. The shares sit well below the 52-week high, and no insider or share-issuance data point is available for this refresh. The company has not announced a date for third-quarter results; the second-quarter date was announced on 31 July 2026, one week before the 6 August 2026 report.

Catalysts, next 30 days

• ~31 December 2026 (est.): end of the guided year-end 2026 clinical window. This falls outside the next 30 days but is the event the case turns on. It is a guidance endpoint, not a scheduled presentation.

Elapsed catalysts

• ~5 November 2026 (est.): third-quarter 2026 results. The company had not confirmed a date as of 23 October 2026; the prior-year report came on 3 November 2025. The filing updates cash, share count and any use of the at-the-market facility. (passed 1d ago)

What would change the view

The clinical premise breaks if additional hepatitis B biopsies show no comparable cccDNA-derived transcript reduction, or if year-end 2026 passes without new biopsy results. A clinical hold, a dose-limiting toxicity or a treatment-related serious adverse event during repeat dosing would also end it.

On price, a weekly close below $6.22, the 25 September 2026 close, would erase the recovery. A third-quarter filing showing a higher share count from at-the-market issuance, with no new clinical data, would weaken the financing leg of the case.

A clear replication of the 1-log result in more patients with clean safety would strengthen it.

What it trades with

No current theme cluster carries this name, and its price depends mainly on its own clinical disclosures. Other clinical-stage gene-editing and gene-therapy developers share financing and sentiment sensitivity. The Duchenne program also places it alongside rare-disease gene-therapy developers, such as iECURE, which reported its own data on 27 August 2026. Company-specific results are likely to dominate until the year-end update.